Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CALAVI: acalabrutinib plus best supportive care in hospitalized COVID-19 pneumonia
jRCT2031230751Completed
- Sponsor
- AstraZeneca
- Start
- Jul 2020
- Modality
- Small Molecules
01
Overview
Randomised trial in coronavirus disease 2019 (COVID-19) and coronavirus pneumonia comparing Acalabrutinib + best supportive care with Best supportive care alone (2 arms). Primary endpoint: Percentage of participants alive and free of respiratory failure at Day 14. Started Jul 2020; status: completed.
02
Drugs
acalabrutinib
03
Conditions
coronavirus disease 2019 (COVID-19)coronavirus pneumonia
Beyond the preview
Go deeper on jRCT2031230751.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031230751.